A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Sponsor
LaNova Medicines Limited
Study ID
NCT06682780
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • LM-2417 — DRUG
    Q2W/Q3W,Intravenous Drip
  • Docetaxel — DRUG
    Q3W,Intravenous Drip
  • Toripalimab/Tirelizumab — DRUG
    Q3W,Intravenous Drip
  • Carboplatin — DRUG
    Q3W,Intravenous Drip
  • Niraparib — DRUG
    QD,Oral Administration
  • Lenvatinib — DRUG
    QD,Oral Administration

Study Details

This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.

Key Dates

Start date
Sep 17, 2025
Status verified
Mar 2025
Primary completion
Dec 25, 2028
Completion
Dec 1, 2029

Study Design

Enrollment
320 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: LM2417 Dose Escalation(Q2W/Q3W)
  • Experimental: LM-2417 combination therapy exploratory
  • Experimental: LM-2417 combination expansion

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: 60 weeks ]

Central Contacts

Related Studies